EB-NK-301
/ Beijing Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 16, 2026
SOLID-NK: Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=60 | Recruiting | Sponsor: Beijing Biotech
New P1/2 trial • Oncology • Solid Tumor • TACSTD2
1 to 1
Of
1
Go to page
1